Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial

CONCLUSIONS: Zinpentraxin alfa treatment did not benefit patients with idiopathic pulmonary fibrosis over placebo. Learnings from this program may help improve decision-making around trials in idiopathic pulmonary fibrosis. Clinical trial registration available at www.CLINICALTRIALS: gov, ID: NCT04552899.PMID:38354066 | DOI:10.1164/rccm.202401-0116OC

Source: Am J Respir Crit Car... - February 14, 2024 Category: Intensive Care Authors: Luca Richeldi Courtney Schiffman J ürgen Behr Yoshikazu Inoue Tamera J Corte Vincent Cottin R Gisli Jenkins Steven D Nathan Ganesh Raghu Simon L F Walsh Parminderjit K Jayia Nikhil Kamath Fernando J Martinez Source Type: research